Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical Genitourinary Cancer|December 3, 2014
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT studyD Jäger, J H Ma, J Mardiak, et al.
Investigational New Drugs|June 28, 2022
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trialM Mego, D Svetlovska, De Angelis V, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodesS Spanik, J Sufliarsky, J Mardiak, et al.
BMC Cancer|February 21, 2016
CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancerM Mego, D Cholujova, G Minarik, et al.
BMC Cancer|July 22, 2015
Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancerM Mego, Z Cierna, P Janega, et al.
Journal of Medical Microbiology|June 1, 1997
Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patientsS Spanik, J Trupl, A Kunova, et al.
International Journal of Antimicrobial Agents|June 13, 1998
Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to methicillin-sensitive bacteriemiaZ Horváthová, S Spánik, J Sufliarsky, et al.
Bratislavske Lekarske Listy|November 1, 1996
Breakthrough bacteraemic and fungaemic episodes during antimicrobial prophylaxis and therapy in cancer patients: analysis of risk factors, etiology, therapy and outcome in 123 episodesS Spánik, V Krcméry, J Trupl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)G Jerusalem, G Mariani, E M Ciruelos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
Pageof 7